 Valeant Pharmaceuticals International Inc., escalating its public campaign to acquire Botox-maker Allergan Inc., threatened to remove members of Allergan's board of directors "if necessary" through a "special meeting.". During a conference call with equity analysts Thursday, Valeant Chief Financial Officer Howard Schiller expressed frustration that Allergan hadn't yet entered negotiations with Valeant and Pershing Square Capital Management, which last month made an unsolicited, $46 billion bid for Allergan....
  